-
Mashup Score: 1
Background Self‐administration of investigational intranasal L‐type calcium channel blocker etripamil during paroxysmal supraventricular tachycardia (PSVT) appeared safe and well‐tolerated in the p…
Source: www.ahajournals.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
The trial achieved its primary efficacy endpoint of terminating PSVT with self-administered etripamil, using symptom-based optional repeat dosing.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
A smaller proportion of patients who used etripamil required an emergency department intervention 5 hours post-administration—compared to placebo users.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
A smaller proportion of patients who used etripamil required an emergency department intervention 5 hours post-administration—compared to placebo users.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 3Efficacy and Safety of Etripamil for Termination of Spontaneous PSVT - American College of Cardiology - 3 year(s) ago
Anthony A. Bavry, M.D., M.P.H., FACC
Source: American College of CardiologyCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Etripamil Nasal Spray Does Not Meet Primary Endpoint in Treating Supraventricular Tachycardia - 4 year(s) ago
May 13, 2020 — The patient-administered nasal spray drug etripamil did not meet its primary endpoint in treating patients with paroxysmal supraventricular tachycardia (PSVT), according to th results of the NODE-301 Trial presented as a late-breaking study at the Heart Rhythm Society (HRS) 2020 virtual meeting.
Source: DAICCategories: Cardiology News and Journals, Latest HeadlinesTweet
NODE-302: Investigational #Etripamil nasal spray for self-treating recurrent #PSVT episodes, with multiple doses allowed. #AHAJournals https://t.co/EeBTnPyK0D https://t.co/rOWSVnxTuB